Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Festival Offer
This Diwali, Light up your portfolio with MoneyWorks4me Superstars starting @ ₹ 7,999 ₹ 5,999 (Offer valid till 3rd Nov 21)
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Twilight Litaka Pharma Ltd Stock Analysis

Small Cap
Evaluated by 83 users | BSE: 506985 | NSE: TWILITAKA |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Jun'13Jun'14TTM
Return on Capital Employed 6.05%22.11%20.35%19.31%17.75%18.83%20.29%7.73%-40.08%-54.44%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 69.515419829537049265773027031.512
Y-o-Y Gr. Rt.-122.3%27.9%49.3%25.6%32.8%33.6%11.1%-63%-88.3%-
Adjusted EPS (Rs.) -0.569.316.568.529.8214.922.541.19-52.57-56.32-59.41
Y-o-Y Gr. Rt.-NA-29.5%29.9%15.3%51.7%51.3%-94.7%-4517.7%NA-
Book Value per Share (Rs.) -1.428.7913.6220.9230.0643.6464.6570.964.24-51.03-58.00
Adjusted Net Profit -0.58.91418.120.931.7483-130-140-147
Net Op. Cash Flow (Rs. Cr.) 3.7-7.3-2.4-18.75.214.2-5.51.5-4.61.7-
Debt to Cash Flow from Ops 8.38-7.95-28.19-6.4231.113.77-47.2199.2-53.06182.54-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Twilight Litaka Pharma Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -8.4%-38.9%-63.7%-88.3%
Adjusted EPS NA-241.8%-235.7%NA
Book Value per Share 0-211.2-192.4-1,303.5
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Jun'13Jun'14TTM
Return on Equity (%) -15.4959.0446.1742.7434.8936.137.371.78-162.75273.08108.98
Operating Profit Margin (%) 4.1210.0313.4512.9813.2113.6414.939.4-12.19-27.7815.29
Net Profit Margin (%) -0.785.767.066.155.646.447.30.4-48.25-443.05-1,178.69
Debt to Equity -22.76.872.312.72.512.11.871.7223.41-2.43-
Working Capital Days 1331151591681931831802034223,261-
Cash Conversion Cycle 48671091231481461421643532,725-
Loading price chart...
Entity Percentage Holding
Promoters 17.28%
Non-Institutions 82.72%
Pledged *98.0891.3772.5872.584.854.854.854.854.850.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Data is not available for this company.

Twilight Litaka Pharma Ltd., formerly Li Taka Pharmaceuticals Ltd. was originally incorporated as Li Taka Pharmaceuticals Pvt. Ltd., on January 18,1974 under the Companies Act, 1956. Thereafter the said company was converted into a Public Limited Company and a fresh Certificate of Incorporation was obtained on December 9, 1985. The company came out with a Public Issue during the year 1986 for expansion, upgradation of its manufacturing facilities.

The company manufactures drugs and

Twilight Litaka Pharma Ltd., formerly Li Taka Pharmaceuticals Ltd. was originally incorporated as Li Taka Pharmaceuticals Pvt. Ltd., on January 18,1974 under the Companies Act, 1956. Thereafter the said company was converted into a Public Limited Company and a fresh Certificate of Incorporation was obtained on December 9, 1985. The company came out with a Public Issue during the year 1986 for expansion, upgradation of its manufacturing facilities.

The company manufactures drugs and formulations in the form of tablets, capsules, ointment and liquids. The company’s products cover the following major therapeutic segments:

  • Analgesics - Anti Inflammatory
  • Anti-Asthmatic
  • Antibiotics
  • Anti-bacterials
  • Vitamins
  • Haematinics
  • Cardiovascular drugs

The company has well equipped, modern manufacturing testing and packaging facilities at all its plants viz. Pimpri, Vadgaon and Vasai. The Pimpri Plant has been approved by Dept. of Science and Technology, Government of India for its R & D facilities. The plants at Vadgaon and Pimpri have also been approved by the Pune University for laboratory use by its students pursuing the Doctorate Degrees.

The facilities at Pimpri and Vadgoan are as per the World Health Organisation guidelines and in conformity with Good Manufacturing Practices (GMP), enabling the company to register its products for exports in several countries all over the world.

The company also has a well established distribution network all over India (except in Delhi and Uttaranchal) with a customer base of over 1,00, 000 doctors for 120 formulations distributed through 1000 stockists. The domestic marketing personnel comprise of over 600 field force and is registered with several Central and State agencies to cater to the requirements of large hospitals, railways, ESIC, GMDs, Post and Telegraph Dept. city contractors, autonomous bodies and armed forces. The company’s business mix also includes an exclusive marketing arrangement with Cipla Ltd. for marketing of its brands across 10 states in the country.

Different divisions of the company:

TL Pharma has five divisions for Domestic Market 

  • TLPL division:This division is also known as the Mother Division as it has products that form Centrum, Nucleus & Zenith divisions. This division holds the promise of very high growth rate in the turnover. This division is ably manned by 225 field personnel.
  • Nutra division :The company has entered the nutraceutical segment with an exclusive division focused on nutritional therapy. The division’s foremost brand is “CALM CREAM” – a nutritional supplement for skin useful in treatment of psoriases and eczema. The focus of this division is on nutraceutical products that are used as adjuvant and support therapy segments like COQ CARE, ARTHRICARE, LBM CARE which will improve the quality of life of the patients.
  • Centrum Division:This division also focuses on servicing specialities like Gynecologists, Paediatricians, Physicians, Surgeons, Orthopaedic Surgeons, General Practitioners. This division has a range of life saving antibiotic injectables vital for use in surgeries & ICUs. Besides there is a range of products like Litacid, Temptal, Epixyl Expectorant & Litacold which provide excellent relief from day to day ailments. This division is ably manned by 400 field personnel.
  • Nucleus divisions :In these two divisions, the focus is on segments like the physicians, general practitioners, orthopaedics, surgeons and paediatricians. Some of their strong brands include Cefilite, Seratid,O1B, Paranac, Toxolite, Antif. The division is ably supported by over 500 field force, 125 Managers and marketed throughout the country
  • Zenith :This division focuses on servicing two specialities of medical practitioners viz. dermatologists and gynaecologists. The fraternity is presented with a range of products prescribed for their patients on a regular basis. This division is supported by 115 field personnel across India, in select towns.

Product range of the company includes:

  • Anti-Inflammatory / Analgesics / Anti-Pyretics
  • Antacids
  • Anthelmintics
  • Antibiotics
  • Anti - Emetics
  • Anti - Fungal
  • Anti - Protozoals Amoebicides
  • Calcium Supplements
  • Coagulants
  • Gynaecology
  • Expectorants / Cold Preparations / Mucolytics
  • Iron - Preparations Folic Acid
  • ORS
  • Vitamins
  • Tranquilizers
  • Topical Preparations
  • Tonics

Milestones:

  • In the year 1974 the company was incorporated as Li Taka Pharmaceuticals Pvt. Ltd
  • In the year 1988 Litaka Laboratories Pvt.amalgamated with the company under approved Scheme of Amalgamation.
  • In the year 1995 Pegasus Laboratories amalgamated with the company under approved Scheme of Amalgamation.
  • The Marketing Division of Borachem Industries was taken over by the company in the year 1997-98.
  • In the year 2000, Clover Pharmaceuticals Private. Amalgamated with the company under approved Scheme of Amalgamation
  • Care Unipac Pvt. merged with the company in pursuance of the order passed by the Hon’ble Bombay  High Court on 28th April, 2006.
  • The Registrar of Companies, Pune issued a fresh certificate in the new name of the company i.e. Twilight Litaka Pharma Limited on 4th July, 2006
  • On 20th October, 2006 the Hon’ble Bombay High Court passed an order confirming the Scheme of Reduction  of Share Capital of the company.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback